A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne
Latest Information Update: 21 Feb 2023
Price :
$35 *
At a glance
- Drugs CJM 112 (Primary)
- Indications Acne vulgaris
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Dec 2023 Results published in the Journal of Dermatological Treatment
- 17 Jun 2022 Status changed from discontinued to completed.
- 02 Nov 2018 Status changed to discontinued.